Ameriprise’s Takeda Pharmaceutical TAK Stock Holding History

Ameriprise’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.07M	Sell	191,809 -2,228	-1%	-$36.9K	﹤0.01%	2851
2026 Q1	$3.59M	Buy	194,037 +13,902	+8%	+$244K	﹤0.01%	2647
2025 Q4	$2.81M	Sell	180,135 -1,196	-0.7%	-$17.1K	﹤0.01%	2819
2025 Q3	$2.65M	Sell	181,331 -82,761	-31%	-$1.23M	﹤0.01%	2857
2025 Q2	$4.08M	Buy	264,092 +179,108	+211%	+$2.65M	﹤0.01%	2512
2025 Q1	$1.26M	Buy	84,984 +19,861	+30%	+$278K	﹤0.01%	3108
2024 Q4	$862K	Sell	65,123 -9,169	-12%	-$126K	﹤0.01%	3310
2024 Q3	$1.06M	Buy	74,292 +19,704	+36%	+$279K	﹤0.01%	3198
2024 Q2	$706K	Sell	54,588 -31,850	-37%	-$422K	﹤0.01%	3311
2024 Q1	$1.2M	Buy	86,438 +4,945	+6%	+$71.9K	﹤0.01%	3096
2023 Q4	$1.16M	Buy	81,493 +1,030	+1%	+$14.6K	﹤0.01%	3126
2023 Q3	$1.24M	Buy	80,463 +4,353	+6%	+$67.4K	﹤0.01%	3046
2023 Q2	$1.2M	Buy	76,110 +3,205	+4%	+$52.5K	﹤0.01%	3095
2023 Q1	$1.2M	Sell	72,905 -25,918	-26%	-$413K	﹤0.01%	3073
2022 Q4	$1.54M	Sell	98,823 -12,959	-12%	-$181K	﹤0.01%	2920
2022 Q3	$1.45M	Buy	111,782 +51,917	+87%	+$722K	﹤0.01%	2943
2022 Q2	$840K	Sell	59,865 -20,818	-26%	-$297K	﹤0.01%	3191
2022 Q1	$1.16M	Buy	80,683 +16,097	+25%	+$236K	﹤0.01%	3149
2021 Q4	$885K	Sell	64,586 -8,316	-11%	-$117K	﹤0.01%	3313
2021 Q3	$1.19M	Buy	72,902 +10,637	+17%	+$179K	﹤0.01%	3093
2021 Q2	$1.05M	Buy	62,265 +1,508	+2%	+$25.7K	﹤0.01%	3204
2021 Q1	$1.11M	Buy	60,757 +16,482	+37%	+$297K	﹤0.01%	3103
2020 Q4	$807K	Sell	44,275 -13,750	-24%	-$241K	﹤0.01%	3181
2020 Q3	$1.03M	Sell	58,025 -125,318	-68%	-$2.28M	﹤0.01%	2953
2020 Q2	$3.29M	Buy	183,343 +137,989	+304%	+$2.48M	﹤0.01%	2345
2020 Q1	$688K	Sell	45,354 -430	-0.9%	-$7.79K	﹤0.01%	2985
2019 Q4	$904K	Sell	45,784 -3,749	-8%	-$71.7K	﹤0.01%	3099
2019 Q3	$851K	Sell	49,533 -5,219	-10%	-$90.3K	﹤0.01%	3085
2019 Q2	$969K	Sell	54,752 -70,307	-56%	-$1.28M	﹤0.01%	3082
2019 Q1	$2.55M	Buy	125,059 +12,069	+11%	+$243K	﹤0.01%	2625
2018 Q4	$1.9M	Buy	+112,990	New	+$1.91M	﹤0.01%	2669

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Ameriprise's TAK Position: Q2 2026 in Review

Ameriprise reduced its Takeda Pharmaceutical (TAK) stake by 1.1% in Q2 2026, selling an estimated $36.9K and leaving 191,809 shares worth $3.07M. The position accounts for ﹤0.01% of the portfolio, ranked #2851.

Ameriprise first reported a position in TAK in Q4 2018 and has held it in 31 quarters since. The position peaked at $4.08M in Q2 2025. 378 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

Ameriprise held 191,809 shares of Takeda Pharmaceutical worth $3.07M as of Q2 2026.
Ameriprise sold 2,228 Takeda Pharmaceutical shares in Q2 2026, an estimated $36.9K.
Takeda Pharmaceutical made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #2851 holding.
Ameriprise first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 31 quarters since.
Ameriprise's Takeda Pharmaceutical position peaked at $4.08M in Q2 2025.
378 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.